Compassionate Use Program

Compassionate Use Program

Providing access to care, serving overlooked populations and working to save lives is at the core of AVM Biotechnology’s mission. As a part of that mission, we are pleased to be able to offer our compassionate use program.

Compassionate use or expanded access programs are designed to make investigational medical products available as early as possible to patients without therapeutic options, because they have exhausted or are not a good candidate for approved therapies and cannot enter a clinical trial. Expanded access refers to the use of investigational drugs outside of a clinical trial, where the primary intent is treatment, rather than research

The purpose of our compassionate use program is to make AVM0703 available to those patients who have exhausted other treatment options and who do not meet the criteria to enroll in a clinical trial. It is intended to improve access to AVM0703 for patients with serious or immediately life-threatening diseases or conditions who lack other therapeutic options and may benefit from it.

It is important to remember that investigational medicinal products have not yet received regulatory approval; thus, their potential risks and benefits are not yet established. Physicians and patients should consider all possible benefits and risks when seeking access to an investigational drug.